\nPfizer Inc. (NYSE: PFE)will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Data from more than 100 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 13 oral presentations and four poster spotlights, will be shared across the company\u2019s approved medicines and expanding portfolio of potential breakthroughs for patients with blood and breast cancers, as well as rare blood disorders.<\/p>\n
\n\u201cOur robust presence at ASH and SABCS reinforces Pfizer\u2019s legacy of scientific innovation for people living with blood disorders and breast cancer,\u201d said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. \u201cWe are pleased to share the latest updates for some of our key approved medicines, including ADCETRIS, ELREXFIO, and IBRANCE, which continue to generate compelling data as foundations of care in their respective indications. We are also excited to present new results in hemophilia and from our expanding pipeline of innovative, next-generation therapy candidates for both blood and breast cancers, including new data on combination approaches across our core scientific modalities.\u201d<\/p>\n
Key ASH Presentations<\/b><\/p>\n
\nData from more than 75 company-sponsored, investigator-sponsored, and collaborative research abstracts will be presented at ASH, including updated analyses from the pivotal ECHELON-3 trial supporting the clinical benefit of ADCETRIS\u00ae<\/sup> (brentuximab vedotin) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL). New data for ELREXFIO\u00ae<\/sup> (elranatamab-bcmm) in relapsed\/refractory multiple myeloma (RRMM) will also be presented from the pivotal MagnetisMM-3 trial, as well as Phase 1 combination data from the MagnetisMM-20 trial. Pfizer will also present updates from its growing Hematology-Oncology pipeline, which includes next-generation CD30 antibody-drug conjugates and other novel and differentiated molecules, including the first presentation of combination data for SEA-CD70 in high-risk myelodysplastic syndromes.<\/p>\n \nAdditionally, Pfizer will present results across its portfolio of investigational and approved medicines in benign hematology.<\/p>\n Key SABCS Presentations<\/b><\/p>\n \nData from 30 company-sponsored, investigator-sponsored, and collaborative research abstracts will be presented at SABCS, including nine real-world analyses affirming IBRANCE\u00ae<\/sup> (palbociclib) as a first-line standard-of-care treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). The company will also present new data from its expanding pipeline of innovative, next-generation therapy candidates that have the potential to address critical unmet patient needs across all subtypes and stages of breast cancer, including new and updated Phase 1 data for atirmociclib, vepdegestrant, and the novel KAT6 inhibitor, PF-07248144.<\/p>\n \nAdditional information on key Pfizer-sponsored abstracts at ASH and SABCS, including date and time of presentation, follow in the chart below. A complete list of Pfizer-sponsored accepted abstracts is available here: https:\/\/www.pfizer.com\/ASH_and_SABCS_2024_Sponsored_Abstracts<\/a>.<\/p>\n\n
\n
\n
\n
\n
\n
\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20241205698751\/en\/1045874\/3\/Pfizer_Logo_Color_RGB_APPROVED.jpg\"){kind=logo}
<\/td>\n<\/tr>\n